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Primary immunodeficiency diseases (PIDs) are inborn errors of 
immunity, a large heterogeneous group of predominantly genetic 
conditions that predispose individuals to a wide spectrum of infection, 
autoimmunity, autoinflammation, lymphoproliferation, malignancy, 
clinically recognisable syndromes in which immunodeficiency is 
a feature, allergic manifestations, and end-organ damage causing 
chronic dysfunction. Without optimal treatment, many PIDs are 
life-limiting.[1] Diagnosis is dependent on the type of infection and 
other presenting manifestations preceding diagnosis, immunological 
testing, and confirmatory genetic testing where possible.[2]
The spectrum of PIDs is evolving rapidly, with new PIDs 
continually being described and molecularly characterised. Since 
1970, the International Union of Immunological Societies (IUIS) has 
included 354 PIDs and 344 different gene defects in its consensus 
classification.[3] Worldwide, PIDs affect more than six million people, 
and in Africa an estimated 988 000 adults and children have PIDs, of 
whom approximately 2 500 have been diagnosed.[4] In South Africa 
(SA), the estimated total population in mid-2017 was 56.52 million. [5] 
If it is assumed that the prevalence of PIDs in SA is similar to that 
in well-resourced countries, the total number of adults and children 
with PIDs in our country should range between 3 040 and 48 775. 
However, fewer than 500 PID cases have been reported from SA.[6,7]
Children with PIDs have been managed at Red Cross War 
Memorial Children’s Hospital (RCWMCH) in Cape Town for more 
than 40 years.[8] An early review of the immunology laboratory 
database at the hospital during a 13-year period identified 93 children 
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Background. The primary immunodeficiency diseases (PIDs) constitute a diverse and ever-expanding group of inborn errors affecting a 
wide range of immune functions. They are not well documented in sub-Saharan Africa.
Objectives. To describe the spectrum of PIDs at a tertiary paediatric hospital.
Methods. A retrospective descriptive study of PIDs diagnosed at Red Cross War Memorial Children’s Hospital, Cape Town, South Africa 
(SA), between 1975 and 2017 was undertaken.
Results. We identified 252 children with PIDs, spanning eight of the nine categories listed in the 2017 classification of the International Union 
of Immunological Societies. Predominantly antibody deficiencies, combined immunodeficiencies with associated syndromic features, and 
immunodeficiencies affecting cellular and humoral immunity accounted for most children with PIDs (n=199, 79.0%). The mean age (standard 
deviation) at diagnosis was 46 (50) months, and the male/female ratio was 1.5:1. There was a history of parental consanguinity in 3 cases (1.2%). 
Recurrent infection was the most prevalent presenting phenotype, manifesting in 177 patients (70.2%). Genetic or chromosomal confirmation 
was obtained in 42/252 cases (16.7%). Common interventions used to prevent infection were antimicrobial prophylaxis and immunoglobulin 
replacement therapy, administered to 95 (37.7%) and 93 (36.9%) of the patients, respectively. Six of 7 children who underwent haematopoietic 
stem cell transplantation (HSCT) had successful outcomes. The 7th patient died 2 months after HSCT from overwhelming infection. Although 
we could not account for the children lost to follow-up during the study period, 53 deaths were confirmed (21.0%).
Conclusions. Several challenges exist in the recognition and treatment of children with PIDs in our setting. These include limited access to 
genetic diagnostics and HSCT. Suboptimal treatment options contribute to the overall mortality of PIDs in SA.
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with PIDs, a mean of 6.6 new PID diagnoses per annum. Primary 
antibody deficiencies predominated, accounting for 56% of all PIDs, 
and the spectrum of PIDs was similar to that reported from Europe 
and North and South America.[9] An analysis of 168 children with 
PIDs managed over a 27-year period at RCWMCH showed that the 
mean age at the time of diagnosis declined significantly over the study 
period, suggesting that awareness of these diseases among clinicians 
had improved.[6] In contrast to the situation in North Africa, where 
PIDs frequently occur in children with consanguineous parents, 
consanguinity was very unusual in the RCWMCH cohort, occurring 
in less than 2% of the patients.[6,10-12] High background consanguinity 
rates in North Africa and the Middle East alter the spectrum of 
PIDs compared with other geographical regions, with autosomal 
recessive conditions being more frequent than X-linked or autosomal 
dominant diseases.[13]
The current IUIS classification of PIDs includes a broad spectrum 
of conditions.[3] At RCWMCH several subspecialist services therefore 
participate in the management of children with PIDs, including 
rheumatology, haematology and oncology, cardiology, allergology, 
pulmonology, gastroenterology and neurology. Previous descriptive 
studies from RCWMCH have been confined to PID patients managed 
by the immunology and infectious diseases services.[9,6]
Objectives
To provide a more comprehensive understanding of the spectrum 
of PIDs across all subspecialist services at our hospital and raise 
awareness of PIDs among SA clinicians.
Methods
Study design and setting
This retrospective, descriptive study was completed at RCWMCH, a 
273-bed, tertiary referral facility in Western Cape Province, affiliated 
to the University of Cape Town. It accepts paediatric referrals from 
various sources in both primary and tertiary settings, providing 
subspecialist consultation to doctors throughout SA but mainly from 
facilities managing children in the Western Cape. A dedicated service 
for the diagnosis and treatment of PIDs was established at RCWMCH 
in the mid-1970s.[14] In 2008 the PID service became part of the 
infectious diseases service at the hospital. Since 1983, information on 
all children with PIDs (i) who were diagnosed and/or treated, or (ii) for 
whom diagnostic/treatment advice was provided to their attending 
clinicians by the PID or infectious diseases services was maintained in a 
dedicated database, henceforth referred to as the PID database. Because 
of the multisystem nature of many PIDs, some children are increasingly 
being managed by subspecialist services other than the infectious 
diseases service at RCWMCH and were therefore not included in the 
PID database. To address this gap in the PID database and describe 
the full spectrum of PIDs managed or supported by all subspecialist 
services at RCWMCH between 1 January 1975 and 31 December 2017, 
the infectious diseases service collaborated with several specialist/
subspecialist services managing children with PIDs.
Classification of PIDs
Patients were classified according to the IUIS 2017 report on in born 
errors of immunity and the IUIS 2017 phenotypic classification,[3,15] 
adapted where necessary using Stiehm’s textbook on immune 
deficiencies.[16] Because mutational analysis is not routinely 
available in SA, most PID diagnoses are based on the clinical and 
immunological phenotype, and the nomenclature used to describe 
specific PIDs was therefore appropriately adapted.[6] Furthermore, 
diagnostic criteria formulated by the Pan-American Group for 
Immunodeficiency and the European Society for Immunodeficiency 
were used to diagnose some conditions such as immunoglobulin A 
deficiency and common variable immunodeficiency.[17]
Data collection
Relevant clinical and laboratory data were extracted from hospital 
folders and the National Health Laboratory Service (NHLS) database 
using a standardised case record form that is used by the infectious 
diseases service in the management of patients with PIDs. Information 
included patient demographics, presenting problems, results of 
immunological investigation, treatment modalities, complications, 
and the outcome if known. The data were transferred anonymously 
in a study-specific Excel spreadsheet, version 2016 (Microsoft, USA).
Data analysis
Data were analysed using Stata statistical software, release 13 
(StataCorp, USA). Proportions were expressed as percentages. 
Continuous variables were tested for normality using the Shapiro-
Wilks test. Means and standard deviations (SDs) or medians and 
interquartile ranges were used to describe the data, as appropriate.
Ethics considerations
The research protocol was approved by the Human Research 
Ethics Committee, Faculty of Health Sciences, University of Cape 
Town (ref. no. 191/2017) and the RCWMCH research committee. 
Patient consent was not obtained, because the analysis was done 
retrospectively. The study was completed in accordance with the 
Declaration of Helsinki.
Results
Patient population
All children entered into the existing PID database during the study 
period were reviewed to confirm the accuracy of their diagnoses. 
Of 230 children in the database reviewed, 12 were excluded because 
there was no conclusive evidence that they had PIDs. The remaining 
218 with PIDs were retained in the study database. Ten other 
specialist/subspecialist services referred 206 children with possible 
PIDs. These 206 patients were derived from outpatient attendance 
lists, clinical databases, the NHLS cytogenetics database and senior 
clinician memory. Clinical and laboratory records of these patients 
were reviewed, and a further 34 appropriately investigated children 
with PIDs were identified and added to the study database. A total of 
252 children with PIDs were therefore identified and included in the 
current analysis (Fig. 1).
Spectrum of PIDs
The number of new PID diagnoses in any 5-year period fluctuated 
throughout the study period, with no clear trend. The 2010 - 2014 
period accounted for the highest number of new PID diagnoses (Fig. 2).
The spectrum of PIDs among the 252 children (Table 1) spanned 
eight of the nine categories listed in the 2017 IUIS report on 
inborn errors of immunity. Among the 252 patients, predominantly 
antibody deficiencies, combined immunodeficiencies with associated 
syndromic features, and immunodeficiencies affecting cellular and 
humoral immunity were most prevalent (Table 1), accounting for 
79.0% of PIDs included in the study.
Patient characteristics
The mean (SD) age at the time of diagnosis was 46 (50) months. The 
male/female ratio was 1.5:1. There were more males than females in 
five of the eight PID categories (Table 1). Thirty-six patients (14.3%) 
were known to have a family history of PIDs. A history of parental 
consanguinity was present in 3 of the children (1.2%), one each with 
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chronic granulomatous disease, severe combined immunodeficiency 
(SCID) caused by a mutation in recombination-activating gene  1 
(RAG1) deficiency, and glycogen storage disease type 1b. The 
majority of the patients (n=181, 71.8%), lived in the Western Cape, 
and a substantial number of patients were in the public health sector 
(Table 2).
Clinical presentation
Recurrent infection was the commonest presenting phenotype, 
manifesting in 177 patients (70.2%). Atypical infection and failure to 
thrive manifested in 38 (15.8%) and 51 (20.2%) patients, respectively. 
Invasive meningococcal infection was the presenting feature in 
9 children with complement component deficiencies, of whom 6 
manifested with recurrent meningococcal infection and 3 with a 
single episode of infection before diagnosis. One child was diagnosed 
after screening based on a family history of complement C5 deficiency. 
Dysmorphic features or recognisable clinical syndromes occurred 
in 52 patients (20.6%). The three commonest syndromes were 
DiGeorge syndrome, formerly called 22q11.2 deletion syndrome, 
ataxia-telangiectasia and hyper-IgE syndrome, occurring in 23 
(9.1%), 15 (6.2%) and 9 (3.6%) of the patients, respectively (Table 1). 
Six of the 7 children with C1 inhibitor deficiency presented with 
angio-oedema, while the remaining patient, an older brother of 
one of the other patients, was screened based on the family history 
and diagnosed before he manifested clinically. The 6 children with 
autoinflammatory disorders presented with non-infectious mani-
festations, commonly persistent fever.
Genetic or chromosomal confirmation
Molecular characterisation is not routinely available in SA, but was 
undertaken in a subset of the patient cohort. Single-gene mutations 
were confirmed in 24 patients in the cohort (9.5%) and chromosomal 
deletions in a further 18 (7.1%) (Table 3).
Management
The predominant interventions administered to prevent infection 
were antimicrobial prophylaxis (95/252, 37.7%) and immunoglobulin 
replacement therapy (93/252, 36.9%). Antimicrobial prophylaxis 
plus immunoglobulin replacement therapy was administered to 
31/252 patients (12.3%). Seven children underwent haematopoietic 
stem cell transplantation (HSCT). The first HCST, for a child with 
SCID caused by interleukin-2 receptor gamma-chain deficiency, 
took place in 1996 (Brian Eley, personal communication 23 July 
2019). Six of the 7 patients had SCID and one immune dysregulation 
polyendocrinopathy enteropathy X-linked (IPEX) syndrome. Six of 
these patients experienced complete immunological reconstitution 
and are well. The 7th patient, who underwent HSCT for underlying 
Patients on infectious 
disease database,
N=230
Patients without 
PID excluded,
n=12
Patients with 
PID included,
n=218
Total patients with 
PID included in the analysis,
n=252
Patients reviewed, N=206
• Haematology, n=60
• Cardiology, n=36
• Cytogenetics, n=73
• Allergology, n=11
• Rheumatology, n=8
• Gastroenterology, n=7
• Neurology, n=4
• Endocrinology, n=3
• Pulmonology, n=3
• Pathology, n=1
Patients with PID, N=34
• Haematology, n=9
• Cardiology, n=7
• Allergology, n=9
• Rheumatology, n=5
• Endocrinology, n=3
• Gastroenterology, n=1
Patients excluded, N=172
• Did not meet the criteria, n=84
• Had no medical record, n=68
• Were on the PID database, n=20
Fig. 1. Selection of patients with PIDs. (PID = primary immunodeficiency disease.)
Fig. 2. Number of new primary immunodeficiency diagnoses, 1975 - 2017.
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Table 1. Spectrum of PIDs, 1975  - 2017
PID category Total, n (%) Males, n/n (%) Females, n/n (%)
Immunodeficiencies affecting cellular and humoral immunity 45 (17.9) 30 15
T–B+ SCID 16 (6.3) 15 1
T–B– SCID 9 (3.6) 2 7
CD40 ligand deficiency 4 (1.6) 4 0
Hyper-IgM syndrome, autosomal 2 (0.8) 0 2
Hyper-IgM syndrome, unspecified 3 (1.2) 2 1
Combined CD4 and CD8 deficiency 8 (3.2) 5 3
Idiopathic CD4 lymphopenia 3 (1.2) 1 2
CD8 deficiency 1 (0.4) 1 0
Combined immunodeficiencies with associated or syndromic features 52 (20.6) 26 26
Wiskott-Aldrich syndrome 4 (1.6) 3 1
Ataxia-telangiectasia 15 (6) 6 9
Chromosome 22q11.2 deletion syndrome 18 (7.1) 10 8
DiGeorge syndrome, genetic defect unknown 5 (2) 2 3
Hyper-IGE syndrome, mutation undefined 7 (2.8) 4 3
Hyper-IgE, with STAT3 mutation 1 (0.4) 1 0
Hyper IgE, without a mutation in STAT3, DOC8 or TYK2 1 (0.4) 0 1
Comel-Netheton syndrome 1 (0.4) 0 1
Predominantly antibody deficiencies 102 (40.5) 66 36
B– panhypogammaglobulinaemia
XL agammaglobulinaemia 18 (7.1) 18 0
AR hypogammaglobulinaemia 2 (0.8) 0 2
B+ hypogammaglobulinaemia
Common variable immunodeficiency 28 (11.1) 18 10
Transient hypogammaglobulinaemia of infancy 25 (9.9) 18 7
Hypogammaglobulinaemia, undefined 3 (1.2) 1 2
Selective IgA deficiency 12 (4.8)) 7 5
IgG subclass deficiency with IgA deficiency 6 (2.4) 1 5
Isolated IgG subclass deficiency 6 (0.02) 3 3
Specific antibody deficiency with normal Ig levels and normal B cells 2 (0.8) 0 2
Diseases of immune dysregulation 2 (0.8) 1 1
Chediak-Higashi syndrome 1 (0.4) 0 1
Immune dysregulation polyendocrinopathy enteropathy XL (IPEX) syndrome 1 (0.4) 1 0
Congenital defects of phagocyte number or function 22 (8.7) 15 7
Congenital neutropenias
Congenital neutropenia, AD inheritance 2 (0.8) 1 1
Glycogen storage disease type 1b 3 (1.2) 1 2
Cyclic neutropenia 1 (0.4) 1 0
Shwachman-Diamond syndrome 1 (0.4) 0 1
Congenital neutropenia, inheritance undefined 5 (2) 3 2
Chronic granulomatous disease, confirmed XL inheritance 1 (0.4) 1 0
Chronic granulomatous disease, AR inheritance 1 ( 0.4) 0 1
Chronic granulomatous disease, mutation undefined 7 (2.7) 7 0
Myeloperoxidase deficiency 1 (0.4) 1 0
Defects in intrinsic and innate immunity 6 (2.4) 4 2
Warts, hypogammaglobulinaemia, infections and myelokathexis (WHIM) syndrome 1 (0.4) 1 0
Chronic mucocutaneous candidiasis 1 (0.4) 0 1
Congenital asplenia with right-sided isomerism 4 (1.6) 3 1
Autoinflammatory disorders 6 (2.4) 4 2
Defects affecting the inflammasome
Familial Mediterranean fever 2 (0.8) 2 0
Mevalonate kinase deficiency (hyper-IgD syndrome) 1 (0.4) 0 1
Non-inflammasome-related conditions
Pyrogenic sterile arthritis, pyoderma gangrenosum, acne (PAPA) syndrome 1 (0.4) 1 0
 Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome 1 (0.4) 1 0
Chronic recurrent multifocal osteomyelitis (CRMO) syndrome 1 (0.4) 0 1
Continued ...
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SCID, died 2 months after HSCT from presumed septicaemia 
complicated by multiorgan failure. Other treatment interventions 
included subcutaneous interferon-gamma administration in 
2  patients with chronic granulomatous disease. The treatment of 
patients with C1 inhibitor deficiency included fresh-frozen plasma 
during acute attacks and tranexamic acid prophylaxis. In the patients 
with autoinflammatory disorders, treatment included colchicine 
(n=3), methotrexate (n=2) and adalimumab, an anti-tumour necrosis 
factor-alpha inhibitor (n=1).
Mortality
During the study period, 53 patients (21.0%) died. The cause of 
death was not known in 12 cases. In the remaining 41 patients, the 
most frequent causes of death were presumed or proven septicaemia 
(n=15, 37.5%) and pneumonia (n=9, 22.5%). Among 47 patients with 
a known date of death, death occurred within 1 year of PID diagnosis 
in 32 cases (68.1%), including 15 (31.9%) who died within 1 month 
of diagnosis. Of the remainder, 7 (14.9%) died between 1 and 5 years 
after PID diagnosis and 8 (17.0%) more than 5 years after diagnosis 
(Table 4).
Discussion
Worldwide, PIDs are an ever-expanding disease group as a result of 
the description of new genetic disorders. The burden of secondary 
immunodeficiencies such as HIV infection and severe acute 
malnutrition continues to overshadow that of the PIDs in low- to 
middle-income countries (LMICs), including SA, resulting in limited 
investment in the diagnostic and treatment resources needed for 
PIDs. Despite the advancing knowledge base and expertise on PIDs, 
national incidence and prevalence estimates are largely unknown. 
An important barrier to care is limited awareness of PIDs and 
their management among healthcare professionals, as well as in the 
broader society. A study completed in the USA and published in 2016 
showed that compared with subspecialist immunologists, few family 
practitioners were aware of guidelines for diagnosing and managing 
PIDs (4% v. 79%).[18] In the present study, we documented the 
spectrum of PIDs among 252 children diagnosed at a tertiary hospital 
in SA over a period of more than 40 years. Although diagnosis 
depended mainly on clinical and immunological criteria, we were 
able to classify our patients using the latest IUIS classification. The 
spectrum of PIDs in this study spanned eight of the nine categories 
in the IUIS classification. The ninth category, phenocopies of inborn 
errors of immunity, was only added to the IUIS classification very 
recently, in 2015, and many of the diseases in this category manifest 
in adulthood, hence the absence of these PIDs among our patients.[3]
Parental consanguinity was identified in only 1.2% of our cases.[13] 
In contrast, in the North African countries of Morocco, Tunisia and 
Egypt, parental consanguinity rates of 43.2%, 58.2% and 62.5%, respec-
tively, were documented.[10-12] These high parental consanguinity rates 
result in higher proportions of PIDs due to Mendelian autosomal 
recessive inheritance, lower proportions of PIDs due to Mendelian 
X-linked inheritance, and consequently a predominance of combined 
cellular and humoral immunodeficiency compared with the 
preponderance of predominantly antibody deficiencies in populations 
with low consanguinity rates.[13] An analysis of the European Society for 
Immunodeficiencies (ESID) registry in June 2014 showed that 56.8% 
of 19 355 children and adults with PIDs had predominantly antibody 
deficiencies.[19] In our study, predominantly antibody deficiencies 
accounted for 40.5% of all PIDs, whereas in the registries of Morocco 
and Tunisia, predominantly antibody immunodeficiencies accounted 
for 22.8% and 17.7% of all PIDs, respectively.[11,12]
The mean age of our patients was 46 months, similar to the mean 
age of children in the Egyptian study of 51 months.[10] The mean ages 
at diagnosis in the Moroccan and Tunisian registries were 6.2 years 
and 5.3 years, respectively.[11,12] However, both these registries included 
children and adults with PIDs. A previous analysis from our hospital 
published in 2011 documented a mean age at diagnosis of 51 months 
and a statistically significant decline in mean age over time, suggesting 
that awareness of the PIDs had increased among clinicians at our 
hospital during the study period.[6] Although most of our patients 
emanated from the public sector, 36.9% were from the private sector. 
Table 1. (continued) Spectrum of PIDs, 1975  - 2017
PID category Total, n (%) Males, n/n (%) Females, n/n (%)
Complement deficiencies 17 (6.7) 7 10
C5 deficiency 2 (0.8) 0 2
C6 deficiency 7 (2.7) 4 3
Complement deficiency, undefined 1 (0.4) 0 1
C1 inhibitor deficiency 7 (2.7) 3 4
All PID categories 252 (100) 153 (60.7) 99 (39.3)
PID = primary immunodeficiency disease; SCID = severe combined immunodeficiency; Ig = immunoglobulin; XL = X-linked; AR = autosomal recessive; AD = autosomal dominant.
Table 2. Patient characteristics at the time of PID diagnosis 
(N=252)
Characteristics
Age (months), mean (SD) 46 (50)
Age category (months), n (%)
<12 76 (30.1)
12 - 60 98 (38.9)
>60 78 (31.0)
Gender, n (%)
Male 153 (60.7)
Female 99 (39.3)
Male/female ratio 1.5:1
Family history of PID, n (%) 36 (14.3)
Parental consanguinity, n (%) 3 (1.2)
Province of residence, n (%)
Western Cape 181 (71.8)
Eastern Cape 25 (9.9)
Gauteng 17 (6.7)
Free State 7 (2.8)
KwaZulu-Natal 6 (2.3)
Northern Cape 8 (3.2)
Unknown 8 (3.2)
Health sector classification, n (%)
Private 93 (36.9)
Public 151 (59.9)
Unknown 8 (3.2)
PID = primary immunodeficiency disease; SD = standard deviation.
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Given that approximately 20% of the SA population are serviced in 
the private sector, this result suggests that more effort may be needed 
to increase awareness of the PIDs among public sector clinicians.
Genetic or chromosomal confirmation of PID diagnosis was 
obtained in 16.7% of our patients, somewhat higher than 13.8% 
genetic confirmation reported in 2015 in the Tunisian registry.[11] In 
Europe, where molecular testing is more accessible, the rate of genetic 
diagnostic confirmation is much higher, having reached 36% of all 
patients registered with ESID registry in April 2018.[20]
Most interventions for managing PIDs are available to a varying 
degree in SA, including optimal immunisation practice, antimicrobial 
therapy and prophylaxis, immunoglobulin replacement therapy 
and infection control measures.[2] Some interventions, such as 
interferon-1 inhibitors and HSCT, are extremely expensive, limiting 
access in the public sector. HSCT is the treatment of choice for many 
severe PIDs. Our findings demonstrate that it is possible to undertake 
HSCT successfully in patients with PIDs in SA. However, only a 
small proportion of more than 50 patients who could have benefited 
received a transplant. Reasons for the low number of transplants 
include late presentation of patients, often with severe complications 
of their underlying PID, the small donor pool in SA, resulting in 
the unavailability of suitable matched unrelated donors, high cost 
of accessing donors affiliated to international registries, and no 
paediatric intensive care facilities at the adult tertiary referral hospital 
where our paediatric transplants were undertaken. In 2012, the first 
HLA-haploidentical HSCT was performed for SCID. Before 2012, 
only HLA-identical or matched unrelated donors were considered 
for children with SCID. Transplantation programmes have also been 
started in North African countries such as Tunisia and Morocco.[11,12]
Unfortunately we had limited access to patient outcomes, especially 
for those lost to follow-up. We are, however, able to describe the 
mortality of 21.0%, which is comparable to mortality documented 
in studies with similar challenges completed in Egypt, Morocco and 
Tunisia of 23.4%, 28.8% and 34.5%, respectively.[10-12] In our study, 
36% of known deaths occurred in patients with SCID, and 68% of 
deaths, including 19 preceded by SCID, occurred during the first 
year after PID diagnosis, indicating the need to focus on optimising 
the outcome of children with SCID because there is a high chance of 
achieving immunological cure after successful HSCT. In the Tunisian 
study, 17.2% of patients were lost to follow-up, suggesting that this 
may be an important outcome in patients with PIDs in other LMICs 
and should be quantified.[11]
Study strengths and limitations
This study is the largest single-centre description of PIDs in children 
in sub-Saharan Africa to date. We were able to include more than 
250 patients because we adopted an expanded search strategy among 
subspecialist services at our hospital. Furthermore, despite limited 
genetic confirmation, we were able to classify our patients using the 
latest IUIS classification system. Because of the retrospective study 
design, there were limitations in the availability and completeness 
of the clinical data. Outcome data were limited to known deaths. 
Because some of the patients were treated by their referring doctors 
with minimal or no feedback, the true mortality prevalence was not 
established and we therefore did not explore risk factors associated 
with death. We could not comprehensively document those who were 
lost to follow-up, and so have an incomplete understanding of the 
true extent of this outcome measure among our patients. Review of 
patients referred by other subspecialist services showed that a sizeable 
proportion were not adequately investigated for immunodeficiency. 
For example, of 73 patients with laboratory-confirmed 22q11 
deletion, 37 (50.7%) had not been investigated for immunodeficiency 
and therefore could not be considered for inclusion in our study 
population. Likewise, of 15 patients with right-sided isomerism, 11 
Table 3. Spectrum of PIDs with confirmed genetic or chromosomal abnormalities
PID Genetic/chromosomal defect Inheritance OMIM Patients, n 
XL agammaglobulinaemia BTK XL 300300 5, related
CD40 ligand deficiency CD40LG XL 300386 3 male siblings
T–B+NK– SCID IL2RG AR 308380 4
T–B–NK+ SCID RAG1 AR 179615 1
Hyper-IgE syndrome STAT3 AD 102582 1
XL chronic granulomatous disease CYBB XL 300481 1
Hyper-IgD syndrome MVK AR 260920 1
C6 deficiency C6 AR 217050 3, unrelated
C5 deficiency C5 AR 120900 2, unrelated
Familial Mediterranean fever MEFV AR or AD 249100
134610
2 male siblings
Immune dysregulation polyendocrinopathy 
enteropathy XL (IPEX) syndrome
FOXP3 XL 300292 1 
DiGeorge syndrome 22q11.2 deletion AD 602054 18, unrelated
PID = primary immunodeficiency disease; OMIM = Online Mendelian Inheritance in Man; XL = X-linked; SCID = severe combined immunodeficiency; Ig = immunoglobulin;  
AR = autosomal recessive; AD = autosomal dominant.
Table 4. PIDs in children who died (N=53) 
PID n (%)
SCID 19 (35.8)
XL agammaglobulinaemia 9 (17.0)
B+ hypogammaglobulinaemia 4 (7.5)
Ataxia-telangiectasia 4 (7.5)
DiGeorge syndrome 4 (7.5)
CD40 ligand deficiency 3 (5.7)
Chronic granulomatous disease 3 (5.7)
Hyper-IgE syndrome, mutation undefined 1 (1.9)
Hyper-IgM syndrome, autosomal 1 (1.9)
Combined CD4 and CD8 deficiency 1 (1.9)
CD8 deficiency 1 (1.9)
Comel-Netherton syndrome 1 (1.9)
Chediak-Higashi syndrome 1 (1.9)
Wiskott-Aldrich syndrome 1 (1.9)
SCID = severe combined immunodeficiency; XL = X-linked; Ig = immunoglobulin.
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had not been investigated for asplenia. Furthermore, it is likely that 
more cases of PID were missed during the study period because 
either PID was not considered or the children presented with milder 
PID phenotypes. Although this reality prevented us from achieving 
complete description of PIDs at our hospital during the study period, 
our results did allow us to largely address the stated objective and 
provide direction for improving our clinical service.
Conclusions
In the present study, we were able to collate the findings of 252 
patients with a spectrum of 50 primary immunodeficiency diseases 
over a period of more than four decades. Greater awareness among 
clinicians treating children and more laboratory diagnostic capacity 
are needed to increase the recognition of PIDs among children in 
SA. The treatment options that are available in SA are unevenly 
distributed. Treatment capacity should therefore be expanded 
throughout the country, especially advanced interventions such 
as HSCT. Ongoing reporting of registries like ours and increased 
community awareness should strengthen the lobby for greater 
investment in rare diseases such as the PIDs.
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